WallStreetZenWallStreetZen

NASDAQ: VYNE
Vyne Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VYNE

Based on 1 analyst offering 12 month price targets for Vyne Therapeutics Inc

Min Forecast
$4.50+400.56%
Avg Forecast
$4.50+400.56%
Max Forecast
$4.50+400.56%

Should I buy or sell VYNE stock?

Based on 1 analyst offering ratings for Vyne Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although VYNE's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates VYNE as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their VYNE stock forecasts and price targets.

VYNE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-25

1 of 1

Forecast return on equity

Is VYNE forecast to generate an efficient return?

Company
-24.17%
Industry
140.91%
Market
90.47%
VYNE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VYNE forecast to generate an efficient return on assets?

Company
-18.9%
Industry
32.45%
VYNE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VYNE earnings per share forecast

What is VYNE's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$1.17
Avg 2 year Forecast
-$0.59
Avg 3 year Forecast
-$0.64

VYNE revenue forecast

What is VYNE's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$600.0k-0.83%
Avg 2 year Forecast
$13.6M+2,147.93%
VYNE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VYNE revenue growth forecast

How is VYNE forecast to perform vs Biotechnology companies and vs the US market?

Company
252.95%
Industry
56.38%
Market
9.68%
VYNE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VYNE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VYNE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VYNE$0.90$4.50+400.56%Buy
LYRA$11.34$16.00+41.09%Hold
MEIP$2.29N/AN/A
IBIO$0.93$5.50+492.67%Strong Buy
SYBX$1.25N/AN/A
View Top Biotech Stocks

Vyne Therapeutics Stock Forecast FAQ

Is Vyne Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: VYNE) stock is to Buy VYNE stock.

Out of 1 analyst, 0 (0%) are recommending VYNE as a Strong Buy, 1 (100%) are recommending VYNE as a Buy, 0 (0%) are recommending VYNE as a Hold, 0 (0%) are recommending VYNE as a Sell, and 0 (0%) are recommending VYNE as a Strong Sell.

If you're new to stock investing, here's how to buy Vyne Therapeutics stock.

What is VYNE's earnings growth forecast for 2025-2027?

(NASDAQ: VYNE) Vyne Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Vyne Therapeutics's earnings in 2025 is -$42,196,000.On average, 2 Wall Street analysts forecast VYNE's earnings for 2025 to be -$19,497,924, with the lowest VYNE earnings forecast at -$22,497,604, and the highest VYNE earnings forecast at -$16,498,243. On average, 1 Wall Street analyst forecast VYNE's earnings for 2026 to be -$9,832,286, with the lowest VYNE earnings forecast at -$9,832,286, and the highest VYNE earnings forecast at -$9,832,286.

In 2027, VYNE is forecast to generate -$10,665,531 in earnings, with the lowest earnings forecast at -$10,665,531 and the highest earnings forecast at -$10,665,531.

What is VYNE's revenue growth forecast for 2025-2028?

(NASDAQ: VYNE) Vyne Therapeutics's forecast annual revenue growth rate of 252.95% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Vyne Therapeutics's revenue in 2025 is $605,000.On average, 1 Wall Street analysts forecast VYNE's revenue for 2025 to be $9,998,935, with the lowest VYNE revenue forecast at $9,998,935, and the highest VYNE revenue forecast at $9,998,935.

In 2028, VYNE is forecast to generate $226,642,531 in revenue, with the lowest revenue forecast at $226,642,531 and the highest revenue forecast at $226,642,531.

What is VYNE's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: VYNE) forecast ROA is -18.9%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is VYNE's Price Target?

According to 1 Wall Street analyst that have issued a 1 year VYNE price target, the average VYNE price target is $4.50, with the highest VYNE stock price forecast at $4.50 and the lowest VYNE stock price forecast at $4.50.

The Wall Street analyst predicted that Vyne Therapeutics's share price could reach $4.50 by Apr 25, 2026. The average Vyne Therapeutics stock price prediction forecasts a potential upside of 400.56% from the current VYNE share price of $0.90.

What is VYNE's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: VYNE) Vyne Therapeutics's current Earnings Per Share (EPS) is -$0.99. On average, analysts forecast that VYNE's EPS will be -$1.17 for 2025, with the lowest EPS forecast at -$1.35, and the highest EPS forecast at -$0.99. On average, analysts forecast that VYNE's EPS will be -$0.59 for 2026, with the lowest EPS forecast at -$0.59, and the highest EPS forecast at -$0.59. In 2027, VYNE's EPS is forecast to hit -$0.64 (min: -$0.64, max: -$0.64).

What is VYNE's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: VYNE) forecast ROE is -24.17%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.